EZH2 and ovarian cancer: Knockdown of EZH2 decreased the level of H3K27 trimethylation (H3K27me3) and enhanced the sensitivity of cisplatin-resistant ovarian cancer cells and tumor xenografts to cisplatin, suggesting a role of EZH2 for cisplatin resistance probably through H3K27 methylation.